Can a psychedelic help break meth addiction in people with HIV?

NCT ID NCT07756736

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial explores whether a single dose of psilocybin, combined with motivational support therapy, can help people with HIV who have moderate-to-severe methamphetamine use disorder reduce or stop their meth use. Participants will be randomly assigned to receive either a higher (25 mg) or lower (5 mg) dose of psilocybin during a monitored session, with therapy visits before and after. The study focuses on whether this approach is feasible, acceptable, and safe, and tracks methamphetamine use for up to three months afterward.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
psilocybin (a psychedelic compound) combined with motivational support therapy
What this could lead to
If successful, this could point toward a new treatment approach for methamphetamine use disorder in people with HIV, potentially improving their health and quality of life.
What could go wrong
This is a small early-phase trial, so results may not apply broadly. Psilocybin can cause intense psychological effects, and its safety in this population is still being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS (HIV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UCSF at Zuckerberg San Francisco General Hospital

    San Francisco, California, 94110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.